Back

Deconvolved tumor adipocyte proportions and high grade serous ovarian carcinoma survival

Ivich, A.; Grieshober, L.; Davidson, N. R.; Akatsu, G. Y.; Peres, L. C.; Hicks, S. C.; Marks, J. R.; Schildkraut, J. M.; Doherty, J. A.; Greene, C. S.

2026-01-19 genomics
10.64898/2026.01.14.699527 bioRxiv
Show abstract

BackgroundSingle-cell-based analyses of high-grade serous ovarian carcinoma (HGSOC) survival have largely ignored adipocytes, which are fragile and under-represented in single-cell references. Adipocytes are known active components of the tumor microenvironment in many cancers, and HGSOC tumors frequently metastasize to the omentum, a lining of adipose tissue. MethodsWe created a composite reference that combines single-nucleus adipose profiles with published HGSOC single-cell data to deconvolve 588 bulk RNA-seq tumours from the Schildkraut cohorts. We used stage-stratified Cox models to quantify the association between intratumoural adipocyte fractions and overall survival while adjusting for age, body mass index (BMI), race, and residual disease. We also evaluated associations with deconvolved immune, stromal, and epithelial cell groups. ResultsA 10% increase in estimated tumor adipocyte content was associated with a 41% increase in the hazard of death (HR = 1.41, 95% CI 1.18-1.70, p = 0.0002) after adjusting for age, BMI and race (n=566). A 10% increase in immune cell proportion was associated with favorable survival (HR = 0.82, 95% CI 0.69-0.97, p = 0.024). Stromal and epithelial macro-fractions were not associated with survival. Associations with adipocyte and immune cell type proportions were unchanged in models additionally controlling the other cell type proportions. Results were similar after additionally adjusting for residual disease after debulking surgery. ConclusionsAdipocytes may be a tumor-intrinsic factor associated with adverse outcomes in HGSOC. Quantifying adipocyte burden using bulk RNA-seq could enhance risk stratification and guide the development of adipocyte-targeted therapies.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
British Journal of Cancer
42 papers in training set
Top 0.1%
12.8%
2
Clinical Cancer Research
58 papers in training set
Top 0.1%
10.2%
3
Annals of Oncology
13 papers in training set
Top 0.1%
8.5%
4
Nature Communications
4913 papers in training set
Top 35%
4.4%
5
BMC Cancer
52 papers in training set
Top 0.6%
3.6%
6
International Journal of Cancer
42 papers in training set
Top 0.3%
3.6%
7
Cancer Research
116 papers in training set
Top 1%
2.9%
8
eLife
5422 papers in training set
Top 32%
2.6%
9
Cell Reports
1338 papers in training set
Top 19%
2.5%
50% of probability mass above
10
Scientific Reports
3102 papers in training set
Top 47%
2.4%
11
JCI Insight
241 papers in training set
Top 2%
2.1%
12
Cell Genomics
162 papers in training set
Top 3%
1.8%
13
Cancer Medicine
24 papers in training set
Top 0.7%
1.8%
14
Nature Medicine
117 papers in training set
Top 2%
1.7%
15
PLOS Computational Biology
1633 papers in training set
Top 16%
1.7%
16
JCO Precision Oncology
14 papers in training set
Top 0.2%
1.5%
17
Cell Reports Medicine
140 papers in training set
Top 4%
1.5%
18
Communications Biology
886 papers in training set
Top 12%
1.3%
19
Genome Medicine
154 papers in training set
Top 6%
1.2%
20
JNCI: Journal of the National Cancer Institute
16 papers in training set
Top 0.5%
1.2%
21
Frontiers in Immunology
586 papers in training set
Top 5%
1.2%
22
PLOS ONE
4510 papers in training set
Top 61%
1.1%
23
Gastroenterology
40 papers in training set
Top 1%
1.1%
24
Endocrinology
38 papers in training set
Top 0.4%
1.0%
25
The Journal of Infectious Diseases
182 papers in training set
Top 4%
0.9%
26
Cancers
200 papers in training set
Top 4%
0.9%
27
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 41%
0.9%
28
PLOS Medicine
98 papers in training set
Top 4%
0.9%
29
Journal of Clinical Investigation
164 papers in training set
Top 5%
0.9%
30
Current Biology
596 papers in training set
Top 12%
0.9%